World Health Organization Sounds Alert Over Acute Shortage of Obesity Jabs

Fewer than 10% of patients eligible to benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it releases its initial guidance on the medications.

Given in excess of 1,000,000,000 people worldwide now obese, it is urging increased and just availability to GLP-1 medication.

Per forecasts, more than two billion could be obese by 2030 without intervention.

"Our new guidelines recognises that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to universal availability to the injections that can help people shift significant weight, explains the organization.

Weight-Loss Drug Shortage

Even under the present most optimistic case, the manufacturing of GLP-1 therapies could only cover about 100 million people – fewer than 10% of eligible patients, per the health organization.

The recommendation calls on governments and firms to expand access, by approaches such as licensing agreements.

The intellectual property rights on a key compound – the primary component of the drug Wegovy – is due to expire in a number of nations in 2026.

The Way Weight-Loss Drugs Work

The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so users consume fewer calories.

People typically start to lose weight in the initial weeks of starting on the once-weekly jabs.

Studies indicates patients may see weight return within a year of discontinuing the drug, when their normal hunger return.

Being carrying excess weight elevates your risk for experiencing diseases, like diabetes, heart disease, brain attack, and specific cancers.

Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.